An Illustrated Guide to Cancer Biology offers a comprehensive exploration of the fundamentals of oncological molecular biology and provides valuable insights into topics such as cancer cell migration, chemotherapeutic drug mechanisms, and the roles of RNA in cancer. With 33 chapters covering a wide array of subjects, including the Hanahan and Weinberg hallmarks of cancer, tumor heterogeneity, and hormone-dependent cancer, this guide serves as an indispensable resource for researchers, students, and practicing oncologists in medicine, oncology, and biochemistry alike. This book stands out not only for its comprehensive coverage of diverse topics but also for its unique approach.
With over 400 figures strategically interspersed throughout the text, this book offers readers a visually engaging journey through the intricacies of cancer biology. These illustrations, ranging from molecular pathways to cellular interactions, make navigating topics like chemotherapeutic drug mechanisms and tumor heterogeneity more accessible. Additionally, the inclusion of sections on repurposing drugs, tumor kinetics, and epigenetics further aids in a deep understanding of cancer biology.
1. Introduction
2. Basics of oncological molecular biology
PART I
3. Basics of oncological molecular biology
PART II: JUNK DNA AND CANCER: POSSIBLE ROLE OF TRANSPOSONS.
4. Basics of oncological molecular biology
Part 3: THE LABORATORY IN MOLECULAR ONCOLOGY. A SYNOPSIS OF THE MOST
IMPORTANT TOOLS
5. Basics of oncological molecular biology
PART 4: SOME BASIC DEFINITIONS
6. The Hanahan and Weinberg hallmarks of cancer
7. Biology of metastasis
8. Mitotic errors, mutations and DNA repair
9. Growth factors, their receptors and proliferative pathways
10. Angiogenesis
11. Hypoxia in cancer
12. The Unique Metabolism of Cancer Cells - Part 1: Carbohydrates
13. The Unique Metabolism of Cancer Cells - Part 2:
14. The Unique Metabolism of Cancer Cells - Part 3:
15. The Unique Metabolism of Cancer Cells - Part 4: Iron metabolism in
cancer
16. Molecular mechanisms of action of chemotherapeutic drugs
17. ROS and cancer
18. Targeted Cancer Treatments - Part I
19. Targeted Cancer Treatments - Part II: Antibody Drug Conjugates for cancer
treatment: present and future
20. Cancer and the immune system - Part I
21. Cancer and the immune system - Part II
22. Cancer and the immune system - Part III: Some caveats about immunology
and cancer. A historical and clinical perspective
23. The tumor microenvironment - Part I: Cancer environment and Groucho
Marxs principles
24. The tumor microenvironment - Part II: CELLS IN THE TUMOR
MICROENVIRONMENT
25. The tumor microenvironment - Part III: Non-cellular components of the
tumor microenvironment
26. The tumor microenvironment Part IV: Adhesion molecules
27. The tumor microenvironment - Part V: Cytokines
28. The tumor microenvironment - Part VI: Chemokines in the TME
29. Tumor heterogeneity: A different way of looking at cancer
30. Resistance to treatment and multidrug resistance (MDR)
31. Pancreatic cancer: a paradigm of difficulties and drug resistance
32. Cancer cachexia
33. Tumor markers
34. The origins and pathogenesis of cancer
35. Extracellular vesicles: Exosomes and microvesicles in cancer. A message
in a bottle.
36. Cancer stem cells
37. Repurposing drugs and nutraceuticals for cancer treatment - PART 1:
General Concept
38. Repurposing drugs and nutraceuticals for cancer treatment - PART 2:
Repurposable Drugs
39. Repurposing drugs and nutraceuticals for cancer treatment - PART 3
Repurposing Metformin
40. Repurposing drugs and nutraceuticals for cancer treatment - PART 4
Repurposable Nutraceuticals
41. The metabolic control center: a survival hub for normal and cancer cells
42. pH homeostasis and ion channels in cancer
43. Tumor growth and genetic evolution - Part I: Tumor growth and kinetics
44. Protein degradation in cancer - Part 1
45. Protein degradation in cancer - Part II : The unfold protein response
(UPR)
46. Cell migration in cancer - Part I: mechanisms of migration and invasion
47. Cell migration in cancer - Part II: Targeting cancer cell migration and
invasion
48. Cell migration in cancer - Part III: The go or grow hypothesis and some
caveats
49. RNA in cancer - Part I: MicroRNAs MiRs or miRNAs
50. RNA in cancer - Part II: Long non-coding RNA (lncRNA)
51. RNA in cancer - Part III: RNA binding proteins (RBPs)
52. Epigenetics and cancer
53. Peroxisome, peroxisome proliferators and peroxisome
proliferator-activated receptors in cancer
54. The renin-angiotensin system signaling pathways and cancer: two sides of
the same coin
55. Hormone-dependent cancer
56.
Chapter 34 Part 1: Cancer and inflammation
57.
Chapter 34 part 2: Links between inflammation and cancer
58.
Chapter 34 part 3: Caveats about anti-inflammatory drugs and cancer
59. Summary and final words
Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Masters in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new triple-edged cancer treatment”. Research in Dr. Fliegels laboratory investigates membrane proteins function, how intracellular pH is regulated and the role of Na+/H+ exchanger in human disease, especially heart disease and breast cancer. The work was funded by CIHR and other sources. Dr. Fliegel has published over 150 publications in numerous journals including J. Biological Chemistry, J. Molecular and Cellular Cardiology, Hypertension, Cancer Research, Basic Research in Cardiology and others. He has authored two books and served on several editorial boards of Journals and grant panels such as CIHR. His awards include a Killam Annual Professor Award (2009-10), a Tier one Basic Science Mentoring Award (2013), McCalla Research Professorship Award (2007) and Alberta Heritage Foundation for Medical Research Scientist Award (2006-2013).
